Extranodal NK/T Cell Lymphoma: Evidence-based Review of Safety and Toxicity of the Available Regimens

Saeed, Hayder; Sokol, Lubomir

doi:10.1016/j.clml.2020.10.006

Cited by 4 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 , 5 , 6 , 7 However, the standard therapy strategies have not yet been established, and the prognosis of patients refractory to the asparaginase-based option or experiencing a relapse or recurrence remains very poor with the current chemotherapy and radiotherapy treatment. 8 , 9 Therefore, further investigations are required to improve the understanding of the pathogenesis and therapeutics of ENKTL.…”

Section: Introductionmentioning

confidence: 99%

Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma

Liu¹,

Ding²,

Li³

et al. 2023

iScience

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma

Liu¹,

Ding²,

Li³

et al. 2023

iScience

View full text Add to dashboard Cite

“…Extranodal natural killer/T-cell lymphoma (ENKTL) re ects non-Hodgkin's lymphoma linked to Epstein-Barr virus (EBV) infection and has a poor prognosis 1,2 . It occurs most commonly in Eastern and central American countries, accounting for 6-17.1% of non-Hodgkin's lymphoma together with an estimated 11.8% of NKTCL in China 3,4 . Due to the low incidence and the lack of international multicenter randomized controlled trials, the optimal treatment for ENKTL is unclear 5,6 .…”

Section: Introductionmentioning

confidence: 99%

Phase II Study of Peg-Asparaginase, Etoposide, Gemcitabine (PEG) Followed by Involved- Field Radiation Therapy in Early-Stage Extranodal Natural Killer/T-Cell Lymphoma

Wang

Yan

et al. 2023

Preprint

View full text Add to dashboard Cite

Background The prognosis of extra-nodal NK-/T-cell lymphoma (ENKTL) is poor and the best therapy controversial. We studied safety and efficacy of a new combined modality therapy.Methods Phase-2 study of peg-asparaginase, etoposide and gemcitabine (PEG) and involved field radiation therapy (IFRT) in newly-diagnosed subjects with early-stage ENKTL. 2–6 course of PEG were given depending on response followed by IFRT. The primary endpoint were complete response(CR),partial response(PR),and objective response rate(ORR) after IFRT. Secondary endpoints included progression-free survival (PFS), survival and adverse events.Results 34 consecutive subjects who were Ann Arbor stage-I/-II were enrolled. 3 subjects progressed on PEG, the remaining 31 received IFRT. The ORR was 88.2%(30/34),included 28(82.4%)complete and 2 ༈5.8%༉ partial responses. At a median follow-up of 56.0 months (Interquartile Range [IQR], 36.0-66.9 months),the 5-year PFS and survival were 87.4% (95% Confidence Interval [CI],69.5%-94.8%) and 97.1% (95%CI,80.1%-99.6%). Most adverse events were haematological and easily managed.Conclusions PEG followed by IFRT is a safe and effective initial therapy for low-stage ENKTL, with similar toxicity and response rates, but higher progression-free survival(PFS) and overall survival(OS) rates compared to other regimens, providing an effective and tolerable new regimen for the newly diagnosed early-stage ENKTL.This conclusion needs validation in a randomized controlled trial.

show abstract

Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Azem¹,

Caddell²,

Nelson³

et al. 2023

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Extranodal NK/T Cell Lymphoma: Evidence-based Review of Safety and Toxicity of the Available Regimens

Cited by 4 publications

References 44 publications

Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma

Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma

Phase II Study of Peg-Asparaginase, Etoposide, Gemcitabine (PEG) Followed by Involved- Field Radiation Therapy in Early-Stage Extranodal Natural Killer/T-Cell Lymphoma

Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Contact Info

Product

Resources

About